Vasculitis & polymyalgia rheumatica
Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study
An erratum to this article was published (RMD Open, Jun 2023 ↗)
Authors' conclusion
In this study, we confirm that tocilizumab is effective in TAK, with complete remission being achieving by 70% of disease-modifying antirheumatic drugs-refractory TAK patients at 6 months.
Study context
- Population
- TAK patients receiving at least 3 months tocilizumab, referral centres in France, Italy, Spain, Armenia, Israel, Japan, Tunisia and Russia, January 2017 to September 2019
- Participants
- 109 patients
- Exposure
- Intravenous vs subcutaneous tocilizumab
- Intravenousn = 91reference
- Subcutaneous (SC)n = 18
- Outcome
- Complete response (NIH <2 with less than 7.5 mg/day of prednisone)
- Follow-up
- 6 months
Methodological detailsmulticentre
- Multicentre
Main finding
As reported in the abstract
Complete response (NIH <2 with <7.5 mg/day prednisone)
P = 0.95
- Complete response overall
- 69%
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Relapse | 2.55 (1.08–6.02) | P = 0.033 | |
| 0.10.31310Hazard ratio (log scale) |
| Outcome | Intravenous | SC |
|---|---|---|
| Cumulative incidence of relapse · 12 months | 10.3% (95% CI 4.8%–18.4%) | 30.9% (95% CI 10.5%–54.2%) |
- Cumulative incidence of relapse — Overall cumulative incidence of relapse
- 13.7% (95% CI 7.6% to 21.5%)
- Relapse: median follow-up 30.1 months (0.4; 105.8) intravenous and 10.8 (0.1; 46.4) SC (p<0.0001)
Factors associated with complete response at 6 months (multivariate analysis)
- Age <30 years, OR 2.85 (95% CI 1.14 to 7.12)
- P = 0.027
- Time between TAK diagnosis and tocilizumab initiation, OR 1.18 (95% CI 1.02 to 1.36)
- P = 0.034
Safety
Adverse events
Original publication
Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study. RMD Open. Published 15 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →